Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.
She has an MPA from New York University. You can connect with Allison on LinkedIn.
Study Examines Clinical Implications of Removing Race From eGFR in CKD
As higher estimated glomerular filtration rate (eGFR) equations indicate better kidney function, there has been increasing recognition that this may lead to inequitable and delayed care in treating chronic kidney disease (CKD) in Black adults.
Trump Targets Drug Prices With 2 Orders Using International Pricing, Ending Rebates
President Donald Trump issued 2 orders Friday aiming to lower drug prices paid by Medicare by invoking a "most favored nations" policy and also by targeting rebates paid to pharmacy benefit managers.
Researchers Develop AI Model to Predict ICI Response in Advanced Melanoma
Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.
Study Indicates ICS May Reduce New Cardiac Events in Patients With COPD
A study looking at chronic obstructive pulmonary disease (COPD) and coronary heart disease found that inhaled corticosteroids (ICS) reduced future cardiac events in patients not known to have coronary heart disease.
Broad Testing for Multiple Genes Benefits Patients With Cancer, Relatives
Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.
Flawed Racial Assumptions in eGFR Have Care Implications in CKD
The use of estimated glomerular filtration rate (eGFR) equations in assessing chronic kidney disease (CKD) for Black patients may lead to underdiagnosis and undertreatment, according to a nephrologist speaking at Kidney Week.
Roxadustat Lowers LDL in Patients With CKD, Anemia
Additional studies about roxadustat, a drug in the new class of hypoxia-inducible factor stabilizers, were released during Kidney Week; one of them explored its role in lowering cholesterol in patients with chronic kidney disease (CKD) and anemia.